Financing channel feed – Endpoints News

Financing channel feed

Pfizer spins off drug orphans into a PhIII-ready startup backed by Bain to the tune of $103M

8 years ago

OrbiMed, RA Capital back a $26M raise for Realm’s two mid-stage drugs

8 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

8 years ago

Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round

8 years ago

Lightstone crew adds a $250M Fund II with plans to back biotech startups

8 years ago

From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world

8 years ago

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

8 years ago

Ex-GSK CEO, R&D chief Andrew Witty and Moncef Slaoui are jumping into the biotech VC game

8 years ago

Harvard biotech wiz Greg Verdine grabs a $55M A round to build a groundbreaking biotech

8 years ago

Cut loose from Biogen buyout option, Rodin preps for an early-stage shot at Alzheimer’s

8 years ago

Sailing past the $2B mark, Flagship sets course for $500M-plus biotech fund, unveils a new startup

8 years ago

Searching for a few great drugs, BridgeBio bags $135M to back a fresh slate of R&D bets

8 years ago

Replimune adds a $55M round and some expert help as it pursues next-gen oncolytics R&D

8 years ago

Google helps boost Gritstone’s neoantigen R&D gamble to $195M as researchers prep for first human study

8 years ago

As China biotech booms, Fidelity group rolls out $250M fund with a big focus on drug R&D

8 years ago

Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall

8 years ago

ASCO spotlight presaged two more biotech IPOs angling for $215M

8 years ago

OrbiMed lines up $551M gamble on China, India biotech sectors

8 years ago

NEA-backed Nightstar Therapeutics sets sights on an $86M IPO to fund PhIII gene therapy study

8 years ago

Star team quietly raises $21M to launch the latest immuno-oncology startup Torque

8 years ago

Celgene, Google double down on Armo’s PhIII immuno-oncology drug with $67M round

8 years ago

Viking leads a $46M raise for a struggling aTyr Pharma

8 years ago

Here’s why 23-year-old Laura Deming is betting $22M on anti-aging R&D

8 years ago

The best — and worst — biotech IPOs in the class of 2017

8 years ago

First page Previous page 138 139 140141142 143 144 Next page Last page